BioPharmSignal logoBioPharmSignal

Biotech News

Erasca to Present at Upcoming Conferences in November

Erasca (ERAS)ErascaCompany update

SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that management will participate in

Related news

ERASErasca2026-11-04 13:30 EST

Tango and Erasca Initiate Phase 1/2 Study of Oral PRMT5 Inhibitor Vopimetostat in Combination with Pan-RAS Molecular Glue ERAS-0015

EXELExelixis2026-11-03 21:05 EST

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November

RLAYRelay Therapeutics2026-11-02 21:05 EST

Relay Therapeutics to Participate in Three Upcoming Investor Conferences in November

MGNXMacroGenics2026-11-05 21:05 EST

MacroGenics to Participate in Upcoming Investor Conferences

STROSutro Biopharma2026-11-04 13:00 EST

Sutro Biopharma to Participate in Upcoming Investor Conferences

SNDXSyndax Pharmaceuticals2026-10-30 11:00 EST

Syndax Announces Participation in November Investor Conferences

ANGOAngioDynamics2026-10-29 12:00 EST

AngioDynamics to Participate in Upcoming Investor Conferences

RVMDRevolution Medicines2026-10-27 20:05 EST

Revolution Medicines to Participate in November 2026 Investor Conferences

CHRSCoherus BioSciences, Inc.2026-10-27 13:30 EST

Coherus to Participate in Upcoming Investor Conferences

INBXInhibrx2026-10-13 20:00 EST

Inhibrx Announces Participation in Upcoming Scientific Conferences

View all latest news

Erasca

RAS/MAPK Precision Oncology Erasca is a clinical-stage precision-oncology company developing therapies for cancers driven by the RAS/MAPK pathway. Its portfolio is designed to address genetically defined tumors through direct RAS inhibition. ERAS-0015 ERAS-0015 is a pan-RAS molecular glue being evaluated in the AURORAS clinical program....

Recent company news

ERASErasca2026-11-04 13:30 EST

Tango and Erasca Initiate Phase 1/2 Study of Oral PRMT5 Inhibitor Vopimetostat in Combination with Pan-RAS Molecular Glue ERAS-0015

ERASErasca2026-11-03 13:00 EST

Erasca to Present at Upcoming Conferences in November

ERASErasca2026-09-10 12:00 EST

Erasca Announces Multiple Presentations at the Upcoming 38th EORTC-NCI-AACR Symposium

ERASErasca2026-09-08 11:00 EST

Erasca to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

ERASErasca2026-08-24 12:00 EST

Erasca Granted FDA Fast Track Designation for Pan-RAS Molecular Glue ERAS-0015 in Patients with Metastatic Pancreatic Adenocarcinoma

Stock data

Close
13.27 USD
Market cap
4.19B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States